This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Non-small Lung Cancer: Draft Evidence Report
This report evaluates the health outcomes and economic effects of certain tyrosine kinase inhibitors (TKIs) and programmed death 1 (PD-1) immunotherapy agents in the treatment of advanced non-small-cell lung cancer (NSCLC). The effects of both classes of agents are evaluated in epidermal growth factor receptor positive (EGFR+) NSCLC, and PD-1 agents are evaluated in EGFR- NSCLC.View All Materials on this Topic or Go Back to View More Materials